[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586484":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":47,"collaborators":31,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":31,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":31,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":31,"overallStatus":35,"whyStopped":31,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Burn ICU patients","EXPERIMENTAL","Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10. Treatment plan will be initiated to all patients according to the burn ICU protocol.",[13],"Diagnostic Test: Interleukin 6",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Interleukin 6","Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10",[9],[21],"Procalcitonin",[23],{"name":24,"affiliation":25,"role":26},"Ahmed H Elsayed, M.B.B.CH","Anaesthesia, intensive care, and pain management resident Ain Shams University","PRINCIPAL_INVESTIGATOR",[28],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","+201016305451",null,"AhmedHanyAbdelfatah@med.asu.edu.eg",[34],{"facility":5,"status":35,"city":36,"state":31,"zip":31,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Cairo","Egypt","EG",{"type":40,"coordinates":41},"Point",[42,43],31.24967,30.06263,{"lat":43,"lon":42},[46],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},{"type":48,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100586484","comparison-between-interleukin-6-and-procalcitonin-in-detecting-sepsis-and-incidence-of-mortality-in-burn-icu-patients-100586484",false,"NCT06915974","Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients","Inclusion Criteria:\n\n* Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.\n* patients with burn percentage of 25% to 50% of total body surface area\n* patients with second to third degree burns\n* ASA 1 and ASA 2 patients\n\nExclusion Criteria:\n\n* Burn percentage more than 50% or less than 25% of total body surface area\n* Having autoimmune diseases\n* Cancer patients\n* ASA 3 and ASA 4 patients","ALL","25 Years","60 Years",{"count":59,"type":60},70,"ESTIMATED","INTERVENTIONAL",[63],"NA","The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.",[66,67,68,69],"Burns","Sepsis","Septic Shock","Death","2025-04-04",{"date":72,"type":73},"2025-04-08","ACTUAL",{"date":75,"type":73},"2025-01-10",{"date":77,"type":60},"2025-07-10",{"name":5,"class":6},1]